FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Catalog category
CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHRP-2/6 and other growth-hormone-axis research peptides and blends.
11 actives in this category · per-lot documented · pricing on request.
What buyers source GH-Axis Peptides for, which buyer types order it, and the documentation that ships with each lot.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
GH-Axis Peptides actives
Modified GRF 1-29 · GHRH analog
Ghrelin / GHSR pathway GH-release peptide
29-mer
GHRH 1-29 fragment
Modified HGH fragment 176–191 (anti-obesity drug candidate)
16-mer
C-terminal fragment of human growth hormone (176–191)
Long-acting GHRH analog with Drug Affinity Complex
Growth-hormone-releasing peptide-2 · Pralmorelin
Growth-hormone-releasing peptide-6
29-mer
GHRH analog · approved for HIV-associated lipodystrophy
Long-Arg3 IGF-1 (long-acting IGF-1 analog)
IGF-1 Ec splice-variant peptide
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
First response under 12 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams review every inquiry before pricing — license verification on every request.
